A possible role for sarcosine in the management of schizophrenia.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31685041.
- Also identified by DOI 10.1192/bjp.2019.194.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sarcosine, which is freely sold as a dietary supplement, has pharmacological activity to boost functioning of the glutamatergic N-methyl-d-aspartate receptor (NMDAR) and hence it is a biologically rational treatment for schizophrenia. The small number of studies carried out to date provide some evidence for its efficacy and psychiatrists could consider suggesting its use to their patients.
Medical subject headings
- Antipsychotic Agents
- Sarcosine
- Schizophrenia